kittredgeihuhyla1951.blogspot.com
Hematide is in a Phase III trial. Renton led Onyx for nearlg 15 years, stepping down in February 2008as CEO, chairman and a member of Onyx’ s board. At the company, he helped negotiate a research, development and commercialization partnership with that resulted inthe anti-cancer drug Nexavar. Nexavar tablets, which cost aboutf $5,000 a month in the Uniteed States and areapproaching $1 billionb in annual sales, are approved in more than 80 countrieds to treat kidney cancer and 70-plus countries for liver Prior to joining Onyx, Rentonn was president and COO of Chiron, which acquirerd Cetus in 1991.
Renton had been presidenrt of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987. Rentoh also serves on the boardsof , Cepheid and the Speciaol Olympics of Northern California.
No comments:
Post a Comment